I help investors and founders validate assumptions about the U.S. healthcare/insurance ecosystem, determine how to close gaps that could stunt product uptake, or come up with alternate use cases.
In 20 years consulting for biotech, medical devices and diagnostics companies, I've seen truly innovative products stall after FDA approval/clearance, and I've seen mediocre products thrive.
The difference is in surfacing and addressing any disincentives that various stakeholders have on using, covering and reimbursing these products. No matter how significant the innovation or impressive the therapy or test performance, these challenges still crop up
